FINWIRES · TerminalLIVE
FINWIRES

Market Chatter: Konica Eyes Commercialization of AI-Powered Microbe Detection System by March 2029

By

-- Japanese imaging product manufacturer Konica Minolta (TYO:4902) plans to commercialize an AI-powered system by March 2029 that uses hyperspectral imaging to reduce the time necessary to select high-yield microbes for food production by over 90%, Nikkei Asia reported Tuesday.

The technology, developed with the National Institute of Advanced Industrial Science and Technology (AIST), replaces manual microscope-based selection with a faster, data-driven system that lowers processing time, the report said.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Related Articles

Sectors

Sector Update: Financial Stocks Gain Pre-Bell Tuesday

Financial stocks were mostly higher pre-bell Tuesday, with the State Street Financial Select Sector SPDR ETF (XLF) gaining by 0.5%.The Direxion Daily Financial Bull 3X Shares (FAS) rose by 1%, and its bearish counterpart Direxion Daily Financial Bear 3X Shares (FAZ) was 1.2% lower.PayPal (PYPL) shares were down more than 10% before the opening bell after the company said it expects to post a roughly 9% decline in Q2 non-GAAP EPS.HSBC (HSBC) stock was down more than 4% after the company reported lower-than-expected Q1 earnings.Banco Santander (SAN) shares were up more than 1% pre-bell after falling 3.1% at the prior close. The bank and Uber Technologies (UBER) said they have agreed to launch a scalable financing platform of up to 1 billion euros ($1.17 billion) to support fleet operators across Europe.

$FAS$FAZ$HSBC$PYPL$SAN$XLF
Research

Research Alert: Iqvia: Encouraging Q1 Results, Eps Guidance Raised Modestly

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:IQVIA reported Q1 2026 revenue of $4,151M (+8.4% Y/Y), led by robust Commercial Solutions growth (+11.6% Y/Y) and steady R&D Solutions performance (+6.2% Y/Y). Adjusted EPS of $2.90 (+7.4% Y/Y) exceeded guidance and beat consensus by $0.08. R&D Solutions bookings were encouraging, in our view, with net new bookings of $2.5B generating a book-to-bill ratio of 1.04x amid what management described as a stabilizing biopharmaceutical market. IQV raised 2026 adjusted EPS guidance to $12.65-$12.95 (up $0.10 at the midpoint) while reaffirming revenue and EBITDA guidance. The contracted backlog of $34.2B supports revenue visibility, with $8.9B expected to convert over the next twelve months (+7.6% Y/Y), though EBITDA margin declined to 22.5% from 23.1%. We view mid-to-high single digit growth in forward-looking demand indicators as suggesting continued client momentum, while the company maintained flexibility with $552M in share repurchases and 15% FCF growth to $491M.

$IQV
Research

Research Alert: Ldos Q1: Revenue Beat And Strong Cash Flow Counter Margin Compression

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:LDOS delivered solid Q1 results with adjusted EPS of $3.13 vs $2.97 prior year, beating consensus by $0.22. Revenue grew 4% Y/Y (+3% organic) to $4.40B, exceeding estimates by $110M, driven by Intelligence, commercial energy infrastructure, and air traffic management demand. The quarter's standout performance was exceptional cash generation, with operating cash flow reaching $301M vs $58M prior year and free cash flow improving to $270M from $36M, delivering 67% conversion driven by solid EBITDA generation and effective working capital management. However, adjusted EBITDA margin contracted 20 bps to 14.0% due to acquisition-related costs. Net bookings of $3.3B resulted in quarterly book-to-bill of 0.8x, though trailing-12-month ratio remained healthy at 1.1x. Total backlog reached $48.4B with funded backlog of $9.6B, representing 4% and 31% Y/Y growth respectively, providing enhanced revenue visibility going forward.

$LDOS